Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease, with astrocytes implicated as contributing substantially to motor neuron death in familial (F)ALS 1-5 . However, the proposed role of astrocytes in the pathology of ALS derives in part from rodent models of FALS based upon dominant mutations within the superoxide dismutase 1 (SOD1) gene, which account for <2% of all ALS cases 2,4,5 . Their role in sporadic (S)ALS, which affects >90% of ALS patients, remains to be established. Using astrocytes generated from postmortem tissue from both FALS and SALS patients, we show that astrocytes derived from both patient groups are similarly toxic to motor neurons. We also demonstrate that SOD1 is a viable target for SALS, as its knockdown significantly attenuates astrocyte-mediated toxicity toward motor neurons. Our data highlight astrocytes as a non-cell autonomous component in SALS and provide an in vitro model system to investigate common disease mechanisms and evaluate potential therapies for SALS and FALS.
Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease, with astrocytes implicated as contributing substantially to motor neuron death in familial (F)ALS [1] [2] [3] [4] [5] . However, the proposed role of astrocytes in the pathology of ALS derives in part from rodent models of FALS based upon dominant mutations within the superoxide dismutase 1 (SOD1) gene, which account for <2% of all ALS cases 2, 4, 5 . Their role in sporadic (S)ALS, which affects >90% of ALS patients, remains to be established. Using astrocytes generated from postmortem tissue from both FALS and SALS patients, we show that astrocytes derived from both patient groups are similarly toxic to motor neurons. We also demonstrate that SOD1 is a viable target for SALS, as its knockdown significantly attenuates astrocyte-mediated toxicity toward motor neurons. Our data highlight astrocytes as a non-cell autonomous component in SALS and provide an in vitro model system to investigate common disease mechanisms and evaluate potential therapies for SALS and FALS.
ALS, commonly referred to as Lou Gehrig's disease, is a fatal neurodegenerative disease characterized by loss of motor neurons in the motor cortex, brain stem and spinal cord. It results in muscle paralysis and ultimately death due to respiratory failure. Approximately 90% of all cases are classified as SALS, defined as having no family history of the disease 6 . The remaining cases are inherited in a dominant fashion, FALS, of which 20% are associated with mutations within SOD1 (ref. 6 ).
Numerous hypotheses have been proposed to account for motor neuron loss. However, the precise molecular mechanisms leading to ALS remain unknown 7 . Studies performed using FALS mouse models have implicated non-neuronal cells such as microglia and astrocytes in the progression phase of FALS 2, [8] [9] [10] [11] . In particular, in vitro coculture systems have shown that motor neurons perish in the presence of astrocytes harboring SOD1 mutations 1, [3] [4] [5] . However, all of these in vitro and in vivo studies have been conducted using models that highly overexpress mutant SOD1, which may not fully mimic the actual disease.
Despite the many notable insights gained from these studies, no efficacious drugs or therapies have been realized in human clinical trials. Indeed, models of ALS have come under scrutiny, given that drugs and therapies are tested in models of FALS, accounting for only a small fraction of ALS patients. Thus, efforts have been focused on developing in vitro cell-based models for SALS, which afflicts the majority of the patient population. Currently, there is a major impetus to develop in vitro cell-based models for ALS, using induced pluripotent stem cell technology 12, 13 . Nonetheless, there are no published reports on SALS models. The generation of SALS disease models will be important to decipher whether astrocytes influence disease progression in SALS, as they do in FALS.
There is reason to suspect that glia are involved in the pathogenesis of SALS, as both FALS and SALS patients show strikingly similar spinal cord pathologies with pronounced glial activation and upregulation of pro-inflammatory mediators and cytokines 14 . Indeed, in our analysis of ALS patient spinal cord samples, we observed increased glial cell numbers, which is indicative of astrocyte activation in the presence of atrophied motor neurons in both FALS and SALS patients ( Supplementary  Figs. 1 and 2) . What remains to be determined is whether SALS astrocytes play an active role in the death of motor neurons, and whether this non-cell autonomous effect can be recapitulated in vitro.
Here, we show that SALS and FALS astrocytes, derived from postmortem spinal cord neural progenitor cells (NPCs), share a common non-cell autonomous toxicity, selectively killing motor neurons in a coculture model system. We observed that inflammatory gene expression is upregulated in astrocytes upon coculture with motor neurons derived from both FALS and SALS patients. In addition, we demonstrate that suppression of wild-type SOD1 in SALS astrocytes is neuroprotective in our model system, further implicating a role for wild-type SOD1 in SALS.
To test whether SALS astrocytes are similarly neurotoxic as FALS astrocytes, we derived astrocytes from adult NPCs isolated from postmortem lumbar spinal cord tissue from one FALS and seven SALS patients. We hypothesized that isolation of NPCs from these individuals After initial expansion of all NPC lines, cells were differentiated into astrocytes by medium supplementation with 10% fetal bovine serum. As NPCs can give rise to multiple cell types in these differentiation conditions, we performed an extensive marker analysis of our established astrocyte cell lines to evaluate the purity of our cultures ( Supplementary  Table 3 ). Indeed, we found high levels of expression of well-known astrocyte markers, including vimentin, glial fibrillary acidic protein (GFAP) and the astrocyte precursor marker CD44 ( Fig. 1a and Supplementary Table 4 ), without evident contamination by other cell types. We found no detectable oligodendroglial progenitors or microglia in our cultures as assessed by immunohistochemistry for NG2 and CD11B, respectively ( Fig. 1a and Supplementary  Table 4 ). The absence of microglia in the cultures was also confirmed by quantitative qRT-PCR for CD11B and IBA1 ( Fig. 1b and Supplementary  Fig. 5 ). Additionally, we evaluated the maturity of astrocytes by measuring expression of a panel of genes known to be enriched in astrocytes in vivo 18 . NPC-derived astrocytes shared a similar gene profile to primary astrocytes isolated directly from the human spinal cord (Fig. 1c) . All of these results suggest that highly enriched astrocyte lines can be derived from NPCs isolated from postmortem spinal cord tissues, which represent a renewable source of human FALS and SALS astrocytes for subsequent analysis.
We next explored whether NPC-derived astrocytes from FALS and SALS patients were toxic to motor neurons by coculturing mouse embryonic stem cell-derived motor neurons with the differentiated astrocytes from each patient. We used an embryonic stem cell line containing an Hb9 motor neuron-specific promoter driving eGFP expression to allow for easy visualization of these motor neurons in coculture with astrocytes 19 . To ensure reproducibility of the experiments, we enriched for Hb9-eGFP + motor neurons by fluorescence-activated cell sorting ( Supplementary Fig. 6 ). Twenty-four hours after plating of the motor neurons onto a confluent layer of astrocytes, we did not find a significant difference in the number of motor neurons present between ALS and control astrocyte cultures ( Fig. 2a) , or in motor neuron soma diameter or length of neuritic extensions up to 48 h after coculture initiation ( Fig. 2b,c) . However, after 96 h in culture, motor neurons that were would provide a renewable source of multipotent cells that could be differentiated into astrocytes and then used for coculture studies with motor neurons, as previously described 15 . Sample collection was coordinated by The National Disease Research Interchange (NDRI) and all tissues were received within 24-72 h of death for immediate processing in our laboratory. Samples were nonidentifiable with the exception of critical information regarding clinical diagnosis, gender, age at death, and length of time from diagnosis to death ( Supplementary Table 1 ).
To purify NPCs from these spinal cords, we used an enzymatic digestion protocol to dissociate the cells, followed by Percoll-gradient NPC enrichment, as previously described ( Supplementary Fig. 3a ) 16, 17 . Within 3-4 weeks, NPC cultures were established, and marker analysis showed robust levels of the NPC marker NESTIN ( Supplementary  Fig. 3b,c) . Furthermore, the NPCs proved to be tripotent, capable of differentiating into neurons, oligodendrocytes and astrocytes ( Supplementary Fig. 3d-f ). NPC cultures were successfully established from one FALS patient harboring an A4V SOD1 mutation ( Supplementary Fig. 4 ), seven SALS patients and one non-ALS control. Further DNA sequencing verified that our cohort of SALS patients did not harbor mutations in common ALS gene loci (Supplementary Table  2 ). To increase the rigor of our analyses, we used two additional non-ALS controls: a fetal human NPC line, SCP-27, and a fetal human primary astrocyte cell line, 1800 ( Supplementary Table 1 ). -27  63358  4944MA  64089  9J003  64391  91095  090322  DIO2  PTN  PTGR1  TTPA  ACOT11  PRODH  BMPR1B  CCL8  GFAP  CYP4F11  ALDH1L1  ATP1A2  PLA2G7  PTGDR  ALDOC  CNTF  PPP1R3C  GMFB  PTGS2  TLR3 ACSBG1 MERTK
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Low High CD11B measured motor neuron survival. Motor neurons cultured in conditioned media from SALS or FALS astrocytes died ~50% faster than motor neurons treated with conditioned media from non-ALS control astrocytes ( Fig. 2e,f) . Conditioned media collected from ALS patient-derived fibroblasts did not cause motor neuron death, demonstrating the specificity of the astrocyte-derived toxicity (Supplementary Fig. 8b ). Likewise, GABAergic neurons were unaffected by treatment with conditioned media prepared from FALS or SALS astrocytes, indicating that motor neurons are selectively sensitive to factors present in the ALS astrocyteconditioned media (Supplementary Fig. 9b ). These results suggest that FALS and SALS astrocytes either secrete factors that are toxic to motor neurons, or alternatively do not provide factors needed for motor neuron survival, resulting in cell death.
To investigate potential causes of the toxicity originating from FALS and SALS astrocytes, we examined genes involved in inflammatory signaling. Previous reports have documented heightened inflammatory gene activation in FALS astrocytes 1, 3 . We used qRT-PCR array technologies to assay the expression of a functionally diverse set of 84 genes that includes both cytokine and chemokine ligands and receptors, and other intermediary signaling proteins all involved in inflammatory gene regulation. Gene expression analysis across several FALS and SALS astrocyte lines revealed that 35-60% of total inflammatory genes assayed were upregulated compared to non-ALS control astrocytes ( Fig. 3 and Supplementary Table 5 ). We observed some heterogeneity among our ALS astrocytes, as expected with a varied disease etiology. However, clustering analysis revealed a set of 22 upregulated genes encompassing chemokines, proinflammatory cytokines, as well as components of the complement cascade, many of which have been previously implicated in ALS 21 (Fig. 3b) .
We next did a network-based pathway analysis using Ingenuity Pathway Analysis software. This identified four networks ranked by a statistical scoring method (Supplementary Table 6 ). The NF-kB signaling complex was identified as a major interactor within the highest ranked network (score = 33), based upon the high number of connections and its centralized cultured on top of FALS astrocytes began to degenerate, as evidenced by atrophy of the motor neuron soma and shortened neurites (Fig. 2b,c) . Indeed, at 120 h following coculture the number of motor neurons present in FALS astrocyte cocultures was significantly (P = 0.004) reduced by 50% compared to non-ALS astrocyte control cocultures ( Fig. 2a,d) . Similar results were observed when either A4V SOD1 or G93A SOD1 transgenes were overexpressed in non-ALS control astrocyte lines ( Supplementary Fig. 7) , supporting previous coculture studies showing toxicity of astrocytes overexpressing mutant SOD1 (refs. 1, [3] [4] [5] 15, 20) .
Next, we shifted our focus to examine whether SALS astrocytes exhibit a similar non-cell autonomous toxicity toward motor neurons. Similar to our previous experiments using FALS astrocytes, we noticed no significant changes in motor neurons cocultured with SALS astrocytes for up to 48 h. However, by 96 h of coculture, motor neurons cocultured with all lines of SALS astrocytes began to degenerate (Fig. 2b) . After 120 h of coculture with SALS astrocytes, there were 45-70% fewer motor neurons compared to non-ALS controls ( Fig. 2a,d) . The motor neuron damage elicited by the SALS patient-derived astrocytes was indistinguishable from that elicited by FALS astrocytes, suggesting a shared mechanism for motor neuron death in both types of cocultures. To verify that the observed motor neuron toxicity was caused by astrocyte-specific factors, we cocultured motor neurons with ALS patient-derived fibroblasts and observed no significant decline in motor neuron survival compared to motor neurons cocultured with control fibroblasts ( Supplementary  Fig. 8a) . To determine whether the FALS or SALS astrocytes affect survival of other neuronal cell types in vitro, we cocultured GABAergic (gamma aminobutyric acid positive) neurons with ALS patient-derived astrocytes. Neither the FALS nor SALS astrocytes triggered death of GABAergic neurons, suggesting the ALS astrocyte-derived toxicity is specific toward motor neurons, thereby adding confidence to our assay ( Supplementary Fig. 9a ). Collectively, these results demonstrate that SALS astrocytes are also toxic toward motor neurons, and support the idea of a disease mechanism common to both FALS and SALS.
Previous work has shown that astrocytes isolated from the FALS SOD1 mouse model can cause motor neuron death in vitro by means of secreted factors 1, 5 . To determine whether our patient-derived FALS and SALS astrocytes also release neurotoxic factors, we treated motor neurons with astrocyte-conditioned media and neuron death using a lentivirus encoding a short hairpin (sh)RNA 24 to specifically knockdown SOD1 levels. Suppression of mutant SOD1 expression in our FALS astrocytes resulted in a full rescue of astrocytemediated motor neuron toxicity as compared to the non-ALS control line (Fig. 4a,b) . As expected, the missense shRNA control did not alter the FALS astrocyte-mediated toxicity toward motor neurons (Fig. 4b) .
The indistinguishable pathological and clinical features of FALS and SALS have long insinuated a shared disease mechanism between these forms of ALS, and recently SOD1 has been proposed as a common link. Several studies have suggested that wild-type SOD1 can adopt conformational changes in SALS patients that make it similar to the known pathological forms of SOD1 mutated in FALS [25] [26] [27] . These findings led us to test whether shRNA-based suppression of wild-type SOD1 in the SALS astrocytes would confer neuroprotection to motor neurons. To test this hypothesis, we performed experiments similar to our SOD1 knockdown in FALS astrocytes. All motor neurons cocultured with SALS astrocytes expressing the missense shRNA control showed location within the interactome (Supplementary Fig. 10 ). Interferon-a was also identified within this gene network interactome. Within the second-highest ranked network (score = 12), we identified pathways involving kinases such as MAPK, JNK and AKT, which establish a high number of interactions with the inflammatory genes ( Supplementary  Fig. 11 ). Many of these signaling networks have been previously implicated in FALS, and we now show evidence for their potential involvement in mediating inflammatory responses in SALS astrocytes 22, 23 .
To increase the confidence of our assays, we determined whether suppression of mutant SOD1 in the FALS astrocytes would rescue motor CCL16  CCL11  CCL20  CXCL1  CXCL5  CXCL6  CCR1  C4A  CEBPB  CCL13  CXCL2  CXCL3  C3  CXCL12  CCL2  IL1R1  CARD18  TNF  CXCL10  CXCL11  IL1F8  SPP1  IL8  CCL7  CCL8  CCR7  CCL3  CCL5  CCR3  CXCL14  IL1A  IL1B  CCL15  CCL1  BCL6  TOLLIP  CCR6  CCR4  CXCCR1  CCL23  CCL18  CCL4  CCR2  CRP  Il8RB  IL1F6  IL1RN  CCL26  CCL25  LTB  IL22  CCR5  IL5  ABCF1  IL13  IL10  IL1F9  IL10RA  IL1F10  SCYE1  IL9  IL9R  CCL19  XCR1  CCL21  IL1F5  C5  IL1F7  IL17C  CCL17  IFNA2  IL10RB  IL13RA1  LTA  CD40LG  LTB4R  CCL24  CCR8  CCR9  CXCL9  IL5RA  CXCL13  IL8RA  MIF   CCL11  CCL20  CXCL1  CXCL5  CXCL6  CCR1  C4A  CEBPB  CCL13  CXCL2  CXCL3  C3  CXCL12  CCL2  Il1R1  CARD18  TNF  CXCL10  CXCL11  IL1F8  SPP1  IL8   Average   63358  64089  91095  9J003  4944MA  64391  63358  64089  91095  9J003  4944MA  64391 Overexpressed gene cluster b a significant (P = 0.001) cell death compared to control line 63358, consistent with previous experiments (Fig. 2d) . Notably, when we suppressed SOD1 in our SALS astrocytes, we observed statistically significant (P = 0.005) neuroprotective effects in four of the six SALS astrocyte lines (Fig. 4b) . In the remaining two SALS astrocyte lines, we observed a trend of neuroprotection, although these results were not significant. This lower level of neuroprotection may reflect, as we observed, that SOD1 was not efficiently suppressed in these lines, as quantified by enzymelinked immunosorbent analysis (ELISA) analysis (Fig. 4c) , even though the level of lentiviral transduction efficiency was equivalent among all the astrocyte lines. Collectively, these results suggest that suppression of SOD1 in SALS astrocytes is beneficial and can confer significant motor neuron protection from ALS astrocyte-derived toxicity, when >50% of wild-type SOD1 knockdown is achieved. These results support previous findings [25] [26] [27] that wild-type SOD1 should be considered a possible therapeutic target for SALS.
A major challenge in the field of ALS research has been to evaluate the similarities and differences between FALS and SALS. Here, we tested whether astrocytes derived from the more common form of the disease, SALS, showed a similar glial-mediated toxicity toward motor neurons as demonstrated in various FALS models. Our results indicate a shared mechanism leading to motor neuron death between FALS and SALS through astrocyte-mediated toxicity. In addition, we provide evidence that wild-type SOD1 is involved in this toxicity, suggesting that therapies targeting SOD1 in astrocytes may be beneficial not only to FALS patients with SOD1 mutations, but also to SALS patients as well. Recently, novel vectors have been shown to efficiently target astrocytes of adult brain and spinal cord 28 and constitute an attractive therapeutic option. Alternatively, astrocyte replacement has also been proposed as a potential therapy for slowing disease progression in ALS, and stem cell transplants are currently in human clinical trials 29 .
Although glia represent a potential therapeutic target in ALS, an ultimate goal in the ALS research field is to understand why motor neurons perish in the disease. Of note, our studies presented here investigated only ALS astrocyte-derived toxicity on non-ALS-derived motor neurons. The derivation of patient-specific motor neurons will be important to further evaluate pathological abnormalities in these cell types. To aid in this endeavor, we recently demonstrated that human motor neurons can be efficiently and rapidly generated from pluripotent stem cells 30 . This novel strategy should be advantageous in generating motor neurons from patient-specific induced pluripotent stem cells. In sum, this work introduces a model system to investigate molecular disease mechanisms and evaluate potential therapies for SALS, and highlights the great potential in using patient-specific samples for studying complex diseases.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturebiotechnology/. containing 10% FBS and plated in a 6-well dish, and within 2 weeks, fibroblasts were usually confluent on a 10-cm 2 tissue culture dish.
Immunocytochemistry. Cells in culture were fixed with 4% PFA for 10 min, followed by three rinses of TBS for 5 min, and then blocked for 1 h with 10% donkey serum with 0.1% Triton X-100. Spinal cord tissue sections were blocked similarly before antibody addition. All primary antibodies were diluted in blocking solution and tissue sections or cells were incubated overnight at 4 °C. Primary antibodies and dilutions used are shown in Supplementary Table 3 . Nuclei were counterstained with DAPI. All images were captured using a Zeiss LSM510-META confocal laser-scanning microscope (Zeiss).
DNA sequencing of ALS patient samples. The SOD1 gene was sequenced in all ALS samples. For SOD1 sequencing, primers were designed that flanked all five exons of the SOD1 within intronic regions. High-fidelity accuprime polymerase (Invitrogen) was used to amplify exonic regions and was subsequently sequenced at Eurofins MWG Operon (Huntsville) using standard Sanger sequencing protocols. In all ALS cases SOD1 coding regions were wild type, except for one familial ALS case containing a C→T transition 14 nucleotides downstream of the start adenine nucleotide rendering an alanine to a valine amino acid substitution at position 4 in the protein (A4V SOD1).
RNA isolation and qRT-PCR. RNA was harvested using the RT 2 q-PCR-grade RNA isolation kit (SABiosciences) and total RNA was reverse transcribed with RT 2 First Strand Kit (SABiosciences) according to the manufacturer's instructions. Real-time quantitative PCR reactions were performed using RT 2 Real-Time SYBR Green/Rox PCR Master Mix (SABiosciences) and PCR arrays were run on an ABI Prism 7000.
Gene array analysis. Astrocyte-enriched gene expression was analyzed in proliferating NPCs, astrocytes, mesenchymal stem cells and primary human astrocytes using a customized RT 2 Profiler PCR Array (SA Biosciences). Inflammatory gene expression was measured in astrocytes cocultured with motor neurons using a cataloged RT 2 Profiler PCR Array for human Inflammatory Cytokines and Receptors (SA Biosciences). All analyses were performed using the web-based PCR Array Data Analysis Software available on the SA Biosciences website. Gene expression was normalized using a set of five housekeeping genes and fold regulation was used to analyze changes in gene expression. Cluster 3.0 was used to cluster the row of genes based on the Euclidean distance, and at the same time cluster the patients based on centered correlation. Unstandardized fold-change values against control were used as input for Clustergram. Phylogenetic trees were displayed by TreeView. The overexpressed inflammatory cluster of genes (also called focus genes) common to all ALS patients was uploaded into IPA 9.0 (Ingenuity Systems). The IPA web tool was used to identify molecular networks that involve these focus genes, which were then ranked by a statistical scoring algorithm with P < 0.001. Interactomes based upon the top two statistically ranked networks were generated by IPA 9.0 by probing the ingenuity knowledge base, which is the largest annotated database of previously published data.
Virus production. SOD1 expression in astrocytes was knocked down by lentiviral transduction expressing short interfering RNA sequences previously described 24 . In addition, lentiviruses were used to overexpress either human wild-type SOD1, G93A SOD1 or A4V SOD1 by the CMV promoter in astrocytes. Viruses were produced by transient transfection into HEK293 cells using calcium phosphate, followed by supernatant viral purification by ultracentrifugation.
Embryonic stem cell motor neuron differentiation. Mouse embryonic stem cells that express GFP driven by the Hb9 promoter (HBG3 cells, kind gift from Tom Jessell) were cultured on primary mouse embryonic fibroblasts (Millipore) and differentiated to motor neurons in the presence of 2 mM retinoic acid (Sigma) and 2 mM purmorphamine (Calbiochem). After 5 d of differentiation, the embryoid bodies were dissociated and sorted for GFP on a FACSVantage/DiVa sorter (Becton Dickinson).
Coculture of motor neurons and astrocytes.
Human astrocytes were plated in 96-well plates coated with laminin (5 mg/ml, Invitrogen) at a density of 10,000 cells per well. Two days after, GFP + motor neurons were sorted by FACS and cultured on top of the astrocytes at a density of 10,000 per well
ONLINE METHODS
Human tissue samples. Post-mortem spinal cord and skin samples were obtained from the NDRI, which had obtained informed consent from all prospective donors. Receipt of human tissues was granted through Nationwide Children's Hospital Institutional Review Board (IRB08-00402, Investigating the Role of Glia in Amyotrophic Lateral Sclerosis), and use of all human samples is in accordance with their approved protocols. Tissues samples were processed ~24 to 72 h postmortem.
Tissue processing for histological analysis. Spinal cord tissues were fixed in 4% paraformaldehyde for 24 h, followed by two rinses of 0.1 M sodium phosphate buffer. Tissues were then transferred to 30% sucrose in 0.1 M sodium phosphate buffer and allowed to incubate for 2 d at 4 °C or until the spinal cords sank to the bottom of the solution. Spinal cord tissues were cut in 5-to 6-mm sections and embedded in Tissue-Tek OCT compound (Sakura Finetek) and frozen with dry ice. Tissues were then sectioned at 10 mm with a cryostat and then stored at -20 °C in an anti-freezing solution before immunocytochemical analysis. For thionin staining, spinal cords were fixed in 4% paraformaldehyde for 24 h, paraffin embedded and sectioned at 8 mm. Sections were then stained for thionin for easy visualization of motor neurons.
NPC isolation and maintenance. All procedures were performed in sterile fashion in a class II biosafety cabinet. A representative portion (2.5 cm) of three regions (thoracic, cervical and lumbar) of the spinal cord was used for NPC isolation, as described previously 16 . Briefly, tissue was diced and a single cell suspension was obtained by enzymatic dissociation of the tissue at 37 °C for ~30-40 min with 2.5 U/ml papain (Worthington Biochem), 250 U/ml of DNase I (Worthington Biochem) and 1 U/ml neutral protease (Roche). After dissociation, the cell suspension was mixed with DMEM/F12 (Invitrogen) with 10% FBS (FBS, Gibco), passed through a 70 mM filter, and centrifuged. The cell pellet was resuspended in DMEM/F12 with 10% FBS and combined 1:1 with Percoll (GE Healthcare). The cell/Percoll mixture was centrifuged at 20,000g for 30 min at 20 °C and the low buoyancy fraction (10 ml) above the red blood cell layer was collected. Cells were washed and resuspended in NPC medium containing DMEM/F12 (Invitrogen) supplemented with 10% FBS (Gibco), 10% BIT9500 (Stem Cell Technologies), 1% N2 supplement (Invitrogen), 20 ng/ml of FGF-2 (Peprotech), 20 ng/ml of EGF (Peprotech) and 20 ng/ml of PDGF-AB (Peprotech). NPCs were cultured on fibronectin (Chemicon) coated plates and after 24 h, the media was replaced with serum-free NPC medium. Half of the medium was subsequently replaced every 2 d. Cells were passaged when 60-70% confluence was reached in about 3-4 weeks. NPC differentiation. Neurons, astrocytes and oligodendrocytes were obtained from NPC cultures by removal of growth factors from the media and supplementation with differentiation factors. To differentiate NPCs into neurons, we supplemented medium with 2 mM all-trans retinoic acid (Sigma) and 5 mM of forskolin (Sigma). To induce astrocytic differentiation, we supplemented NPCs with 10% FBS (Gibco). Oligodendrocyte differentiation was induced by culturing cells in 200 ng/ml of IGF-1. In all conditions, cells were allowed to differentiate for 1 week.
Astrocyte culture and maintenance. Once NPC cultures from ALS patients and controls were established, astrocytes were generated by media supplementation with 10% FBS. Astrocytes were cultured on laminin-coated plates and medium was changed every 3 d. Astrocytes were passaged when 80% confluent. Fetal human NPCs, isolated from the frontal brain cortex of a 28-week term fetus, (SCP-27, cell passage 1, P1) were obtained from the National Human Neural Stem Cell Resource. Human fetal astrocyte cell line (1800) isolated from cerebral cortex was obtained from ScienCell research laboratories.
Skin fibroblast isolation and maintenance. In brief, a 2 cm 2 skin sample was rinsed twice in PBS and then placed in a 10-cm 2 dish with the epidermal side facing down. The subcutaneous layer was then scraped off using a surgical scalpel and cut into 0.5-cm 2 strips. Skin tissue was then allowed to incubate with 25 ml of 0.05% trypsin/EDTA (Invitrogen) in a 50-ml conical tube at 37 °C for 45 min with gentle agitation every 15 min. After the incubation period, 20 ml of DMEM media containing 10% FBS was added to inactivate the trypsin and cells were pelleted at 350g for 4 min. Cells were then resuspended in DMEM media nature biotechnology doi:10.1038/nbt.1957 followed by chemiluminescence (ECLTM Western Blotting Detection Reagents, Amersham Biosciences). The blots were then stripped and re-probed with a b-actin antibody (#A5060, Sigma-Aldrich, 1:1,000) to control for protein loading. To evaluate the levels of SOD1 knockdown in SALS, SOD1 isozyme was analyzed by ELISA (Abnova). Elisa was performed in 75 ng of cell lysate following manufacturer's recommendations.
GABAergic neuron differentiation. Mouse fetal neural progenitors were cultured on laminin-coated plates (5 mg/ml, Invitrogen) in Neural Stem Cell Media (DMEM:F12 (Invitrogen) and 5% N2 (Invitrogen)). GABAergic neurons were differentiated from mouse fetal neural progenitors in DMEM:F12 (Invitrogen) with 0.1% FBS (Invitrogen), retinoic acid (1 mM, Sigma), and forskolin (5 mM, Sigma) for 7 d.
Statistical analyses. All statistical tests were performed by multiway analysis of variance followed by a Bonferroni post hoc analysis of mean differences between groups (GraphPad Prizm Software). Experiments were performed in triplicate or quadruplicate.
in motor neuron media (DMEM:F12 (Invitrogen), 5% horse serum, 2% N2 (Invitrogen), 2% B27 (Invitrogen) + GDNF (10 ng/ml, Invitrogen), BDNF (10 ng/ml, Invitrogen), CNTF (10 ng/ml, Invitrogen)). After 24 h, cytosine arabinose (1 mM) was added for 48 h to eliminate any remaining dividing NPCs or embryonic stem cells. Media was changed every other day subsequently. For the astrocyte conditioned media experiments, media was collected from the coculture every 2 d, supplemented with GDNF, CNTF and BDNF, and added to motor neurons that were cultured on laminin coated plates.
Quantification of SOD levels. Quantification of SOD 1 levels in NPCs derived astrocytes lines was performed either by western blot or Elisa. For western blot, cell lysates were obtained using Tissue Protein Extracting Reagent (TPER, Pierce) and 20 mg of protein was loaded onto a NuPAGE 4-12% Bis-Tris gel (Invitrogen). The proteins were run at 150 V for 1 h then transferred to an Invitrolon PVDF membrane (Invitrogen). The membrane was blocked in 5% nonfat milk, 0.1% Tween-20 in TBS for 1 h and then incubated overnight in primary antibody to human SOD1 (#2770, Cell Signaling, 1:1000). Bound primary antibody was detected by horseradish peroxidase conjugated secondary antibody (Jackson)
